5 Things For Consideration In Addressing Viral Infections
Understanding the sequential process behind a virus infection is key. Not just for COVID-19, but for any other virus that can get into our bodies via the inhalation of airborne droplets or aerosols.
As the global economy starts to regain its footing and people start going out again, the concern about the COVID-19 pandemic shifts to when a second wave of infections may appear.
That’s a valid concern. We have seen how infectious this virus is, and how severe the consequences of an unmitigated infection can be.
And of course, Gilead isn’t going to let this money spinner get away from them. As CNBC reports, Gilead will be selling their remdesivir for a good chunk of moolah:
The majority of patients treated with remdesivir will receive a five-day treatment course using six vials of remdesivir, the company said. That would bring the government cost to $2,340 for patients on the five-day treatment and $3,120 for commercially insured patients.
The longer, 10-day treatment course will cost governments $4,290 per patient and $5,720 for a U.S. patient with private insurance.
